Research Paper Volume 9, Issue 12 pp 2695—2716

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas

Figure 3. Ribociclib and palbociclib lower viability of SW-13 and NCIH295R adrenocortical cell lines. Cells were treated with drugs during 96 h. (a) Mitotane alone (from 1 μM to 100 μM) or combined with CDK inhibitors dose-response bar graphs on SW-13 and NCIH295R cells. CI50 = 50% Combination indexes. (b) Ribociclib and palbociclib dose-response bar graphs on SW-13 (left panel) and NCI-H295R cells (right panel). Drug concentration ranges from 0.05 μM to 20 μM. For each measurement error bars indicate standard deviation value, estimated from two different experiments. Asterisks show the significant t-tests (p values < 0.05).